European Commission grants conditional marketing authorisation to remdesivir (Veklury) for treatment of COVID-19

The license is for the treatment of COVID-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen and follows the CHMP recommendation from 25 June 2020.

SPS commentary:

The Department for Health and Social Care have issued an interim clinical commissioning policy to define routine access to the remdesivir in the treatment of COVID-19 across the UK.


European Medicines Agency

Resource links:

UK Interim Policy for Remdesivir